The FDA has approved Actavis‘ ANDA for Lamotrigine Orally-Disintegrating Tablets, a generic equivalent to GlaxoSmithKline’s Lamictal ODT.

Lamictal ODT is an antiepileptic drug used as an adjunct in partial seizures, Lennox-Gastaut syndrome, or primary generalized tonic clonic seizures in adults and children.  It is also indicated for the treatment of bipolar disorder.

Lamotrigine Orally-Disintegrating Tablets will be available in 25mg, 50mg, 100mg, and 200mg strengths. Actavis intends to launch the product immediately.

For more information visit